Close

Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma Jan 5, 2022 08:00AM
Exelixis Announces CABOMETYX® in Combination with OPDIVO® Provides Efficacy Benefits Regardless of Prior Nephrectomy in Patients with Previously Untreated Advanced Renal Cell Carcinoma Based on Chec Sep 16, 2021 02:30AM
Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell C Aug 25, 2021 04:05PM
Exelixis (EXEL) Announces Consistent Efficacy Benefits Across Subgroups of Phase 3 CheckMate -9ER Trial of CABOMETYX in Combination with OPDIVO as First-line Treatment for Patients with Advanced RCC Jun 4, 2021 09:01AM
Exelixis Announces Quality-Adjusted Survival Benefit Demonstrated in Analysis of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Pr Jun 4, 2021 09:00AM
View Older Stories

Jun 4, 2021 09:00AM Exelixis Announces Consistent Efficacy Benefits Across Subgroups of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-line Treatment for Pa
Mar 31, 2021 01:01AM Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as First-Line Treatment for Patients with Advanced Renal Cell Ca
Mar 30, 2021 08:00AM Exelixis Announces Enrollment Completion in Phase 3 COSMIC-313 Pivotal Trial of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanc
Feb 26, 2021 06:40AM Exelixis' (EXEL) Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX in Combination with OPDIVO as First-Line Treatment for Patients with Advanced RCC
Feb 26, 2021 06:30AM Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcino
Feb 8, 2021 05:00PM Exelixis Announces Positive Findings at ASCO GU for CABOMETYX® (cabozantinib) in Patients with Brain Metastases from Renal Cell Carcinoma
Jan 22, 2021 01:10PM Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
Oct 27, 2020 05:51AM Exelixis (EXEL), Takeda Pharma & Ono Pharma Report Submission of Supplemental Application for CABOMETYX (cabozantinib) in Combination with OPDIVO (nivolumab) in Japan
Oct 27, 2020 01:02AM Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable, Advanced or Metastatic Rena
Sep 21, 2020 10:21AM Exelixis (EXEL) Announces Results From Two Renal Cell Carcinoma Cohorts of the COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab
Sep 21, 2020 10:20AM Exelixis Announces Results From Two Renal Cell Carcinoma Cohorts of the COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab
Aug 24, 2020 08:04AM Exelixis (EXEL) Announces Submission of sNDA to U.S. FDA for CABOMETYX in Combination With Opdivo for Advanced Renal Cell Carcinoma
Aug 24, 2020 08:00AM Exelixis Announces Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for CABOMETYX® (cabozantinib) in Combination With Opdivo® (nivolumab) for Advanced Renal Cell
Jul 20, 2020 08:06AM Exelixis (EXEL) Begins CONTACT-03 Phase 3 Pivotal Trial of Cabozantinib in Combination with Atezolizumab in Previously Treated Metastatic RCC
Jul 20, 2020 08:00AM Exelixis Announces Initiation of CONTACT-03 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Renal Cell Carcinoma
Mar 25, 2020 03:01AM Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) Tablets for the Treatment of Curatively Unresectable or Metastatic Renal Cell Carcinoma
May 1, 2019 05:25PM Exelixis (EXEL) Commences Phase 3 Pivotal Trial (COSMIC-313) of Cabozantinib in Combination with Nivolumab and Ipilimumab
May 1, 2019 04:06PM Exelixis Initiating Phase 3 Pivotal Trial (COSMIC-313) of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinom
Apr 25, 2019 06:42AM Exelixis (EXEL) Reports Partner, Takeda Pharmaceutical, to File NDA in Japan for CABOMETYX (Cabozantinib) for Advanced RCC
Apr 25, 2019 06:30AM Exelixis’ Partner Takeda Announces Filing of New Drug Application in Japan for CABOMETYX® (Cabozantinib) for Advanced Renal Cell Carcinoma
Oct 22, 2018 06:50AM Exelixis (EXEL) Highlights Results from Dose-Escalation Stage of Phase 1b COSMIC-021 Study of Cabozantinib in Combination with Atezolizumab
Oct 22, 2018 06:45AM Exelixis Announces Results from the Dose-Escalation Stage of the Phase 1b COSMIC-021 Study of Cabozantinib in Combination with Atezolizumab in Previously Untreated Advanced Renal Cell Carcinoma
Oct 22, 2018 06:17AM Exelixis (EXEL) Highlights Results from Two Analyses Evaluating Effect of PD-L1 Expression or Prior Treatment with Checkpoint Inhibitors on Efficacy of Cabozantinib
Oct 20, 2018 08:45AM Exelixis Announces Results from Two Analyses Evaluating Effect of PD-L1 Expression or Prior Treatment with Checkpoint Inhibitors on Efficacy of Cabozantinib in Patients with Advanced Renal Cell Carcin
Sep 19, 2018 07:33AM Exelixis (EXEL) Partner Ipsen Reports Health Canada’s Approval of CABOMETYX (cabozantinib) Tablets
Sep 19, 2018 07:32AM Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma
Sep 19, 2018 07:32AM Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma
Sep 7, 2018 08:15AM Exelixis (EXEL) Reports New Recommendations for CABOMETYX (Cabozantinib) Tablets in Updated National Comprehensive Cancer Network Clinical Practice Guidelines
Sep 7, 2018 08:00AM Exelixis Announces New Recommendations for CABOMETYX® (Cabozantinib) Tablets in Updated National Comprehensive Cancer Network Clinical Practice Guidelines
May 17, 2018 05:59AM Exelixis (EXEL) Partner Ipsen Reports European Commission Approval of CABOMETYX (Cabozantinib)
May 17, 2018 01:01AM Exelixis’ Partner Ipsen Announces European Commission Approval of CABOMETYX® (Cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
Mar 23, 2018 06:04AM Exelixis (EXEL) Reports Positive CHMP Opinion for CABOMETYX (cabozantinib)
Mar 23, 2018 02:05AM Exelixis’ Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
Dec 19, 2017 02:59PM Exelixis (EXEL) Confirms FDA Approval of CABOMETYX Tablets for Previously Untreated Advanced RCC
Dec 19, 2017 02:54PM Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
Oct 16, 2017 07:00AM Exelixis (EXEL) Granted U.S. FDA Priority Review for CABOMETYX as Treatment for Previously Untreated Advanced Renal Cell Carcinom
Oct 16, 2017 06:59AM Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX® (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma
Sep 11, 2017 05:55AM Exelixis (EXEL) & Ipsen Reports Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib at ESMO 2017
Sep 9, 2017 06:12PM Ipsen and Exelixis Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017
Sep 9, 2017 06:09PM Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017
Aug 16, 2017 07:04AM Exelixis (EXEL) Submits sNDA for CABOMETYX for Treatment of Previously Untreated Advanced Kidney Cancer
Aug 16, 2017 07:00AM Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX® (cabozantinib) for the Treatment of Previously Untreated Advanced Kidney Cancer
Jul 10, 2017 08:06AM Bristol-Myers Squibb (BMY) & Exelis (EXEL) Commence Phase 3 Trial of Opdivo in Combination with CABOMETYX or Opdivo & Yervoy in Combination with CABOMETYX
Jul 10, 2017 08:00AM Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo® in Combination with CABOMETYX™ or Opdivo and Yervoy® in Combination with CABOMETYX, Versus Sunitinib in Previously Untreated Adv
Jun 19, 2017 03:15PM Ipsen and its partner Exelixis announce independent radiology committee review confirms results from Phase 2 CABOSUN trial of cabozantinib versus sunitinib in previously untreated advanced renal cell
Jun 19, 2017 08:01AM Exelixis (EXEL) Reports Independent Radiology Committee Review Confirms Results from CABOSUN, the Phase 2 Trial of Cabozantinib Versus Sunitinib
Jun 19, 2017 08:00AM Exelixis Announces Independent Radiology Committee Review Confirms Results from CABOSUN, the Phase 2 Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma
Oct 10, 2016 06:16AM Exelixis (EXEL) Announces Statistically Significant Data from Cabozantinib Phase 2 in RCC
Oct 10, 2016 02:15AM Exelixis Announces Positive Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at ESMO 2016
Oct 10, 2016 02:15AM Ipsen and Its Partner Exelixis Announce Positive Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at the European Soc
View Older Stories